Masteron is an injectable anabolic steroid comprising 100mg/mL of Drostanolone Propionate, a compound known for its anabolic and androgenic properties. Initially developed as an anti-estrogen agent for breast cancer treatment in conjunction with Tamoxifen (Nolvadex), a Selective Estrogen Receptor Modulator (SERM), Masteron effectively reduced estrogen levels in patients. Despite its diminished use in medical settings, Masteron remains highly regarded among athletes, particularly competitive bodybuilders, for its performance-enhancing benefits.

Masteron’s anti-estrogenic effects stem from its derivation from DHT (dihydrotestosterone) and its inability to aromatize into estrogen. This characteristic may result from either inhibiting the aromatase enzyme or blocking estrogen’s binding to its receptor. Consequently, Masteron is beneficial for users of aromatizable steroids, predominantly testosterone-based cycles, by preventing estrogenic side effects such as gynecomastia and water retention.

Furthermore, Masteron enhances the concentration of active free testosterone in the bloodstream by obstructing the conversion of free testosterone into estrogen and reducing SHBG. It also mitigates the adverse effects associated with elevated estrogen levels. Additionally, despite its seemingly moderate androgenicity, Masteron exhibits pronounced androgenic effects due to its DHT derivation. However, it suppresses natural testosterone production, rendering it unsuitable for post-cycle therapy aimed at hormonal recovery.

Masteron is particularly effective in cutting phases for competitive bodybuilding, attributed to its capability to counteract estrogen-induced water retention. Users frequently report experiencing fuller, tighter muscles and significant muscle pumps during workouts. The recommended dosage ranges from 400-800 mg/week for men and 50-200 mg/week for women.